![]() ![]() Gilead acquired Kite Pharma in October 2017 for $11.9 billion. Listen to this article 3 min Biopharmaceutical company Kite Pharma will expand its footprint in Frederick County with a new warehouse that will bring 100 new jobs to the area, the. Neoantigens are mutations found on the surface of cancer cells that are unique to each person and tumor. Gilead Sciences Kite Pharma unit has carved out a niche for its CD19-targeted CAR-T therapy Tecartus in acute lymphoblastic leukaemia (ALL) in Europe. The Maryland site will support the work of a new Cooperative Research and Development Agreement with the National Cancer Institute to develop adoptive cell therapies targeting patient-specific tumor neoantigens. Kite has also leased a 26,000-square-foot facility in Gaithersburg, Maryland. In addition to the Netherlands facility, Kite has recently purchased a new building in Santa Monica from Astellas Pharma that will be used for cell-therapy research, development, and the expansion of clinical manufacturing capabilities. The new facility is scheduled to be fully operational in 2020. Perettie most recently led Roche’s molecular lab division, and previously was CEO of the Roche-owned. ![]() The facility will engineer and produce cell therapies, including axicabtagene ciloleucel, a chimeric antigen receptor T cell therapy that is currently under review by the European Medicines Agency and which was approved in October 2017 in the US as Yescarta for treating adult patients with relapsed or refractory large B-cell lymphoma. Gilead Sciences on Tuesday named former Roche executive Cindy Perettie as the next head of its cell therapy business Kite Pharma, moving quickly to fill the vacancy left by Christi Shaw, who stepped down from the role at the end of March. The 117,000-square-foot site will be used to manufacture and deliver cell therapies to people living with cancer in Europe. MAINZ, Germany & SANTA MONICA, Calif.- (BUSINESS WIRE)- BioNTech SE (Nasdaq: BNTX, BioNTech) and Kite, a Gilead Company (Nasdaq: GILD, Kite) today announced the closing of the acquisition of the solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility’s assets and leases in Gaithersburg, MD, from Kite. BioNTech has found a use for some of the windfall cash it has raked in from its COVID-19 vaccine, agreeing a deal to buy Kite Pharma's entire neoantigen T cell receptor (TCR) platform for solid. Kite has leased a new facility in Hoofddorp, the Netherlands to engineer cell therapies. 74 GADOLINITE and samars- kite, new elements in, 13, 27 Gadolinium. Kite Pharma, Gilead Sciences’ cell-therapy subsidiary, has leased and purchased new facilities in the US and Europe to expand its cell-therapy manufacturing capabilities. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |